The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

Time：

2025-07-24

Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration.

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration. This product was approved for marketing under the category of Class 4 chemical drugs, with specifications of 4.6mg/24 hours and 9.5mg/24 hours, deemed to have passed the consistency evaluation. Rivastigmine transdermal patch This is the company's first approved patch, with the approved indication being: for the treatment of mild to moderate Alzheimer's disease symptoms.

Rivastigmine is a carbamate-type brain-selective acetyl- and butyrylcholinesterase inhibitor. Its mechanism of action is to slow the degradation of acetylcholine released by functionally intact cholinergic neurons, thus contributing to cholinergic neurotransmission. Data from animal studies suggest that Alzheimer's disease is associated with cholinergic-mediated cognitive deficits, and rivastigmine may selectively increase the expression of acetylcholine in the cerebral cortex and hippocampus, potentially improving cholinergic-mediated cognitive deficits.

The launch of the rivastigmine transdermal patch further enriches the company's product line, providing a new option for a large number of Alzheimer's disease patients. The company will actively promote the marketing and sales of this product in the future.

Tags:

previous

None

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

Next

Related News

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

2025-07-24

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

2025-07-16

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

2025-06-19

Share

Back to list